Starting a TNF inhibitor within 1 year of the onset of back pain may not improve clinical outcomes or drug retention compared ...
Kids with polyarticular-course juvenile idiopathic arthritis (JIA) who received a second tumor necrosis factor (TNF) inhibitor after failing one initially did just as well as those who changed to a ...
Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...
Please provide your email address to receive an email when new articles are posted on . Tumor necrosis factor-alpha inhibitors incited partial (53.2%) and complete clearance (40.4%) in patients with ...
Tumor necrosis factor (TNF) inhibitors led to no significant difference in survival or respiratory-related hospitalizations compared with non-TNF inhibitors, in patients with rheumatoid ...
The FDA continues to receive reports of hepatosplenic T-Cell lymphoma (HSTCL) in adolescents and young adults treated for Crohn’s disease and ulcerative colitis with tumor necrosis factor (TNF) ...
ELV001 aiming to disrupt the treatment paradigm for patients with incomplete response to standard of care (methotrexate + TNF inhibitors)Phase 2b ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune ...
ATLANTA — According to new research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated ...
MedPage Today on MSN
Medicare coverage appears spotty for newer rheumatoid arthritis meds
Advantage plans do a better job than standalone Part D policies, albeit with important gap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results